In a recently reported study [24] that assessed the prognostic role of aromatase expression in NSCLC patients, lower levels of the enzyme predicted a higher probability of survival in women aged 65 years or older. The gene discussed is CYP19A1; the disease is non-small cell lung carcinoma.